These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 34325596)

  • 1. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and
    Alanazi MM; Alaa E; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Taghour MS; Eissa IH
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1732-1750. PubMed ID: 34325596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
    Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
    Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-
    Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Elwan A; Elkady H
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1093-1114. PubMed ID: 34056992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers.
    Alanazi MM; Eissa IH; Alsaif NA; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Elkady H; Elwan A
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1760-1782. PubMed ID: 34340610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
    Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
    Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
    Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
    Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
    El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
    Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies.
    Elkady H; Mahdy HA; Taghour MS; Dahab MA; Elwan A; Hagras M; Hussein MH; Ibrahim IM; Husein DZ; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
    Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(6):130599. PubMed ID: 38521471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
    Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
    Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies.
    Alsaif NA; Mahdy HA; Alanazi MM; Obaidullah AJ; Alkahtani HM; Al-Hossaini AM; Al-Mehizi AA; Elwan A; Taghour MS
    Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100359. PubMed ID: 34862634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New [1,2,4]triazolo[4,3-c]quinazoline derivatives as vascular endothelial growth factor receptor-2 inhibitors and apoptosis inducers: Design, synthesis, docking, and antiproliferative evaluation.
    Azab AE; Alesawy MS; Eldehna WM; Elwan A; Eissa IH
    Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200133. PubMed ID: 35822666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors.
    Abdallah AE; Mabrouk RR; Al Ward MMS; Eissa SI; Elkaeed EB; Mehany ABM; Abo-Saif MA; El-Feky OA; Alesawy MS; El-Zahabi MA
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):573-591. PubMed ID: 35012403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, semi-synthesis, anti-cancer assessment, docking, MD simulation, and DFT studies of novel theobromine-based derivatives as VEGFR-2 inhibitors and apoptosis inducers.
    Eissa IH; Yousef RG; Elkady H; Elkaeed EB; Alsfouk AA; Husein DZ; Ibrahim IM; Elhendawy MA; Godfrey M; Metwaly AM
    Comput Biol Chem; 2023 Dec; 107():107953. PubMed ID: 37673011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.
    Yousef RG; Eldehna WM; Elwan A; Abdelaziz AS; Mehany ABM; Gobaara IMM; Alsfouk BA; Elkaeed EB; Metwaly AM; Eissa IH
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and
    Hagras M; Saleh MA; Ezz Eldin RR; Abuelkhir AA; Khidr EG; El-Husseiny AA; El-Mahdy HA; Elkaeed EB; Eissa IH
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):380-396. PubMed ID: 34923885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
    Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
    Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and
    Elkady H; Elwan A; El-Mahdy HA; Doghish AS; Ismail A; Taghour MS; Elkaeed EB; Eissa IH; Dahab MA; Mahdy HA; Khalifa MM
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):397-410. PubMed ID: 34961427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
    El-Metwally SA; Abou-El-Regal MM; Eissa IH; Mehany ABM; Mahdy HA; Elkady H; Elwan A; Elkaeed EB
    Bioorg Chem; 2021 Jul; 112():104947. PubMed ID: 33964580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.